GlycoMimetics (NASDAQ:GLYC – Get Free Report) released its earnings results on Thursday. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05, Zacks reports.
GlycoMimetics Stock Performance
GLYC stock traded up $0.02 during midday trading on Thursday, hitting $0.28. The company’s stock had a trading volume of 725,304 shares, compared to its average volume of 305,374. The firm’s 50-day moving average is $0.26 and its 200-day moving average is $0.24. GlycoMimetics has a 12 month low of $0.14 and a 12 month high of $3.36.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on GlycoMimetics in a research report on Monday. They issued a “sell” rating for the company.
About GlycoMimetics
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
Further Reading
- Five stocks we like better than GlycoMimetics
- How to Calculate Return on Investment (ROI)
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- What is the Dogs of the Dow Strategy? Overview and Examples
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Using the MarketBeat Dividend Yield Calculator
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.
